Skip to contentV
Viridian Therapeutics, Inc.
V
VRDNViridian Therapeutics, Inc. Q1 2019 · 10-Q
Revenue$372.00K$372.00K−92.2% vs Q1 2018 Net Income-$11.63M-$11.63MN/M vs Q1 2018 EPS Diluted-$0.38-$0.38N/M vs Q1 2018 Operating Income-$11,736,000N/M Operating Cash Flow
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Viridian Therapeutics, Inc. · CIK 1590750 · Engraved from SEC EDGAR
Free Cash Flowderived-$11,846,000N/M Margins · derivedOperating margin-3154.8%−3058.3 pt vs Q1 2018
Net margin-3126.1%−3028.6 pt vs Q1 2018
ended Mar 31, 2019 · filed May 9, 2019 · 39 d after period end